The underestimated risk of additional ipsilateral BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients
Abstract
Objective: To determine the prevalence of malignancy of additional ultrasound BI-RADS category 3 lesions in women with newly diagnosed breast cancer.
Materials and methods: Between July 2014 and June 2022, women with newly diagnosed breast cancer and additional ultrasound BI-RADS 3 lesions were retrospectively included. Malignancy was confirmed by pathology, and malignancy rates were assessed at both the patient and lesion levels. Independent risk factors for malignant BI-RADS 3 lesions were identified using multivariable logistic regression.
Results: A total of 1458 women (median age, 45 years; IQR: 40–51) with 1995 ultrasound BI-RADS 3 lesions were included. At the patient level, malignancy was identified in 3.5% of patients (51/1458), with higher rates for ipsilateral than contralateral BI-RADS 3 lesions (9.8% [39/397] vs 1.1% [12/1061]; p < 0.001). At the lesion level, the overall malignancy rate was 2.7% (54/1995), similarly elevated for ipsilateral compared with contralateral lesions (7.5% [41/544] vs 0.9% [13/1451]; p < 0.001). Independent predictors for malignancy of ipsilateral BI-RADS 3 lesions included same-quadrant location as the primary lesion (OR, 4.3; 95% CI: 1.9, 9.7; p < 0.001), ultrasonographic architectural distortion of the primary lesion (OR, 8.5; 95% CI: 1.6, 46.1; p = 0.01), and mammographic suspicious calcification of the primary lesion (OR, 2.9; 95% CI: 1.4, 6.0; p = 0.004).
Conclusion: Additional ipsilateral ultrasound BI-RADS 3 lesions in women with newly diagnosed breast cancer demonstrated malignancy rates exceeding the 2% BI-RADS threshold, particularly when located in the same quadrant as the primary cancer.
Key Points: Question The malignancy risk of additional BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients remains unclear.
Findings Ipsilateral lesions, especially in the same quadrant, show malignancy rates exceeding 2%, while malignancy risk remains low for contralateral BI-RADS 3 lesions.
Critical relevance statement Ipsilateral BI-RADS 3 lesions in the same quadrant as the primary cancer, or those with primary tumor architectural distortion or suspicious calcifications, warrant biopsy. This ensures precise surgical planning and avoids missing additional malignancy.
Related
- Assessing the impact of additional inclusion criteria on the representativeness of EHR-based long COVID cohorts identified using U09.9
- Preoperative prevalence and risk factors for thromboembolic events following tibial plateau fractures: a retrospective analysis of an underestimated risk.
- Comparative analysis of intracranial pressure prediction models using optic nerve sheath diameter and additional ultrasound metrics
- Core needle biopsy washout biomarkers combined with ultrasound for preoperative axillary risk stratification in breast cancer: a retrospective nomogram study with temporal validation
- Habitat-based ultrasound radiomics for preoperative prediction of axillary lymph node metastasis in breast cancer: a two-center study
BibTeX
@article{hu2026underestimated,
title = {{The underestimated risk of additional ipsilateral BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients}},
author = {Yue Hu and Hongli Wang and Mengzi Wu and Wei Zheng and Jingsi Mei and Xiaofang Jiang and Queran Lin and Ran Gu and Fengtao Liu and Jinna Lin and Chang Gong and Jun Shen and Qiang Liu},
journal = {Insights into imaging},
year = {2026},
month = oct,
doi = {10.1186/s13244-026-02366-6},
url = {https://europepmc.org/article/PMC/PMC13675164},
note = {CC BY},
}
RIS
TY - JOUR
TI - The underestimated risk of additional ipsilateral BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients
AU - Yue Hu
AU - Hongli Wang
AU - Mengzi Wu
AU - Wei Zheng
AU - Jingsi Mei
AU - Xiaofang Jiang
AU - Queran Lin
AU - Ran Gu
AU - Fengtao Liu
AU - Jinna Lin
AU - Chang Gong
AU - Jun Shen
AU - Qiang Liu
PY - 2026
DA - 2026/10/16
JO - Insights into imaging
DO - 10.1186/s13244-026-02366-6
UR - https://europepmc.org/article/PMC/PMC13675164
AB - Objective: To determine the prevalence of malignancy of additional ultrasound BI-RADS category 3 lesions in women with newly diagnosed breast cancer. Materials and methods: Between July 2014 and June 2022, women with newly diagnosed breast cancer and additional ultrasound BI-RADS 3 lesions were retrospectively included. Malignancy was confirmed by pathology, and malignancy rates were assessed at both the patient and lesion levels. Independent risk factors for malignant BI-RADS 3 lesions were identified using multivariable logistic regression. Results: A total of 1458 women (median age, 45 years; IQR: 40–51) with 1995 ultrasound BI-RADS 3 lesions were included. At the patient level, malignancy was identified in 3.5% of patients (51/1458), with higher rates for ipsilateral than contralateral BI-RADS 3 lesions (9.8% [39/397] vs 1.1% [12/1061]; p < 0.001). At the lesion level, the overall malignancy rate was 2.7% (54/1995), similarly elevated for ipsilateral compared with contralateral lesions (7.5% [41/544] vs 0.9% [13/1451]; p < 0.001). Independent predictors for malignancy of ipsilateral BI-RADS 3 lesions included same-quadrant location as the primary lesion (OR, 4.3; 95% CI: 1.9, 9.7; p < 0.001), ultrasonographic architectural distortion of the primary lesion (OR, 8.5; 95% CI: 1.6, 46.1; p = 0.01), and mammographic suspicious calcification of the primary lesion (OR, 2.9; 95% CI: 1.4, 6.0; p = 0.004). Conclusion: Additional ipsilateral ultrasound BI-RADS 3 lesions in women with newly diagnosed breast cancer demonstrated malignancy rates exceeding the 2% BI-RADS threshold, particularly when located in the same quadrant as the primary cancer. Key Points: Question The malignancy risk of additional BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients remains unclear. Findings Ipsilateral lesions, especially in the same quadrant, show malignancy rates exceeding 2%, while malignancy risk remains low for contralateral BI-RADS 3 lesions. Critical relevance statement Ipsilateral BI-RADS 3 lesions in the same quadrant as the primary cancer, or those with primary tumor architectural distortion or suspicious calcifications, warrant biopsy. This ensures precise surgical planning and avoids missing additional malignancy.
SN - 1869-4101
ER -